Clinical Trial Update: XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether Xaliproden can reduce neurotoxicity from oxaliplatin plus 5-FU/leucovorin in metastatic colorectal cancer; the study has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Xaliproden (Xaliproden)

Snippet

Sponsor: Sanofi | Conditions: Metastases, Colorectal Neoplasms | Phase 3 | Status: COMPLETED